期刊
BIOCHEMICAL SOCIETY TRANSACTIONS
卷 37, 期 -, 页码 1243-1247出版社
PORTLAND PRESS LTD
DOI: 10.1042/BST0371243
关键词
angiogenesis; asymmetric dimethylarginine (ADMA); dimethylarginine dimethylaminohydrolase (DDAH); motility; nitric oxide; Rho GTPase
资金
- British Heart Foundation [PG/07/004]
ADMA (asymmetric dimethylarginine) is a cardiovascular risk factor and an endogenous inhibitor of NOS (nitric oxide synthase). ADMA is metabolized by DDAHs (dimethylarginine dimethylaminohydrolases). ADMA levels are increased in cardiovascular disorders associated with abnormal angiogenesis but the mechanisms are poorly understood. Recent studies show that altering ADMA metabolism in vivo and in vitro modulates the activity of Rho GTPases, key regulators of actin dynamics, endothelial cell motility and angiogenesis. in the present review, we consider this and other No-dependent and -independent molecular mechanisms by which the DDAH/ADMA pathway regulates angiogenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据